Current Drug Managements of Wilson’s Disease: From West to East

Title:Current Drug Managements of Wilson’s Disease: From West to East

Volume: 14 Issue: 4

Author(s): Wen-Jie Li, Chen Chen, Zhi-Fei You, Ren-Min Yang and Xiao-Ping Wang

Affiliation:

Keywords: D-penicillamine, dimercaptosuccinic acid, hepatolenticular degeneration, sodium dimercaptosuccinate, tetrathiomolybdate, trientine, Wilson’s disease, zinc.

Abstract: Wilson’s disease (WD), also called hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism characterized by the multiple mutations in the ATP-ase 7B gene of chromosome 13q. About half of the WD patients have neurological or psychiatric symptoms. As WD is a kind of medicable or nearly curable neurodegenerative disease in the field of medicine, early consideration/examination and without delay/ life-long treatment usually lead to better prognoses. The drugs, also named as anticopper agents, are commonly used in clinics including D-penicillamine, trientine, sodium dimercaptosuccinate, dimercaptosuccinic acid, zinc and tetrathiomolybdate. This provides detailed reviews about these medicines.

Cite this article as:

Li Wen-Jie, Chen Chen, You Zhi-Fei, Yang Ren-Min and Wang Xiao-Ping, Current Drug Managements of Wilson’s Disease: From West to East, Current Neuropharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570159X14666151130222427